MedTrace Logo

Chemoradiotherapy of NSCLC Stage IIIB

NCT00198432 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-03-10

No results posted yet for this study

Summary

To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

Conditions

  • NSCLC Stage IIIB
  • Concomitant Radiochemotherapy

Interventions

DRUG

Paclitaxel, vinorelbine, cisplatin

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Pierre Fabre Laboratories

    collaborator INDUSTRY

  • Ligue contre le cancer, France

    collaborator OTHER

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Pierre Fournel, Dr · Intergroupe Francophone de Cancerologie Thoracique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Completion
2006-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198432 on ClinicalTrials.gov